Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): The EORTC STBSG experience

Annals of Surgical Oncology

Volumn 20, Issue 9, 2013, Pages 2937-2943

  Rutkowski, Piotr ^a   Gronchi, Alessandro ^b   Hohenberger, Peter ^c   Bonvalot, Sylvie ^d   Schöffski, Patrick ^e   Bauer, Sebastian ^f   Fumagalli, Elena ^b   Nyckowski, Pawel ^g   Nguyen, Buu Phuc ^f   Kerst, Jan Martijn ^h   Fiore, Marco ^b   Bylina, Elzbieta ^a   Hoiczyk, Mathias ^f   Cats, Annemieke ^h   Casali, Paolo G ^b   Le Cesne, Axel ^d   Treckmann, Jürgen ⁱ   Stoeckle, Eberhard ^j   De Wilt, Johannes H W ^k   Sleijfer, Stefan ^l   Tielen, Ronald ^k   Van Der Graaf, Winette ^k   Verhoef, Cornelis ^m   Van Coevorden, Frits ^h   more..

^a INSTITUTE OF ONCOLOGY   (Poland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j INSTITUT BERGONIÉ   (France)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ERASMUS MC CANCER INSTITUTE   (Netherlands)

^m ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ADVANCED GASTROINTESTINAL STROMAL TUMOR; AGED; CANCER SURGERY; CONFERENCE PAPER; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DUODENUM; ESOPHAGUS; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; ILEUM; JEJUNUM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RECTAL DRUG ADMINISTRATION; RECURRENT DISEASE; STOMACH;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL RATE;

EID: 84881476440     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3013-7     Document Type: Conference Paper

References (41)

1. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14-24.
2. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-5.
3. Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer. 2011;11:72. doi: 10.1186/1471-2407-11-72.
4. Bonvalot S, Eldweny H, Péchoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13(12):1596-603.
5. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003;89:460-4.
6. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093-103.
7. DeMatteo R, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1079-104.
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
9. Doyon C, Sideris L, Leblanc G, Leclerc YE, Boudreau D, Dube P. Prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor. Results of a phase II trial. Int J Surg Oncol. 2012;2012:761576. doi: 10.1155/2012/761576.
10. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011;129(11):2533-42. doi: 10.1002/ijc.26234.
11. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42-7.
12. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739-45.
13. Frankel TL, Chang AE, Wong SL. Surgical options for localized and advanced gastrointestinal stromal tumors. J Surg Oncol. 2011;104(8):882-7. doi: 10.1002/jso.21892.
14. Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol. 2006;32:961-3.
15. Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2012;19(4):1051-5. doi: 10.1245/s10434-011-2191-4.
16. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14:526-32.
17. Hohenberger P, Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Ann Surg Oncol. 2010;17(10):2585-600.
18. Hohenberger P, Langer C, Pistorius S, Iesalnieks I, Wardelmann E, Reichardt P, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol. 2006;24:9500 (meeting abstracts).
19. Hohenberger P, Wardelmann E. Gastrointestinale Stromatumoren. Der Chirurg. 2006;77(1):33-40.
20. Hohenberger P, Licht T, Dimitrakopoulou-Strauss A, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol. 2009;27:15s.
21. Hohenberger P, Langer C, Wendtner CM, et al. (2012) Neoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors. ASCO 2012 Annual Meeting abstract 10031.
22. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265-72.
23. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265-74.
24. Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, Chemy NI. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs. 2004;15:599-602.
25. Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. J Natl Compr Canc Netw. 2012;10:1477-82.
26. LeCesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. J Clin Oncol. 2009;27:3969-74.
27. Liu CL, Huang MJ, Lin SC, Chang KM, Tzen CY. Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour. ANZ J Surg. 2004;74:289-90.
28. Lo SS, Papachristou GI, Finkelstein SD, Conroy WP, Schraut WH, Ramanathan RK. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum. 2005;48:1316-9.
29. Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol. 2005;58:779-81.
30. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910-9.
31. NCCN Clinical Practice Guidelines in Oncology. (2012) Soft Tissue Sarcoma. Version 2.2012.
32. Rutkowski P, Nowecki ZI, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006;4:304-11.
33. Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther. 2008;12:131-43.
34. Rutkowski P, Przybyl J, Zdzienicki M. Extended adjuvant therapy with imatinib in patients with gastrointestinal stroma tumors. Mol Diagn Ther. 2013. doi: 10.1007/s40291-013-0018-7.
35. Salazar M, Barata A, Andre S, Venancio J, Francisco I, Cravo M, Nobre-Leitão C, et al. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut. 2006;55:585-6.
36. Shah JN, Sun W, Seethala RR, Livolsi VA, Fry RD, Ginsberg GG. Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc. 2005;61:625-7.
37. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii49-55.
38. Tielen R, Verhoef C, van Coevorden F, et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol. 2013;39(2):150-5.
39. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-34.
40. Wang D, Zhang Q, Blanke CD, et al. (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Erratum in: Ann Surg Oncol. 2012;19(7):2420.
41. Yoon KJ, Kim NK, Lee KY, Min BS, Hur H, Kang J, Lee S. Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor. J Korean Soc Coloproctol. 2011;27(3):147-52.